About Lysophosphatidic acid receptor 4
Lysophosphatidic acid receptor 4 (LPAR4) is a protein
from Homo sapiens identified by UniProt accession
Q99677, 370 residues long.
MolForge cross-references it against 0 known binders and
57 disease associations.
Target properties
| Protein name | Lysophosphatidic acid receptor 4 |
|---|
| UniProt accession | Q99677 |
|---|
| Gene | LPAR4 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 370 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (57)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.37
- glioblastoma multiforme · score 0.25
- ovarian cancer · score 0.24
- breast adenocarcinoma · score 0.24
- thyroid gland adenocarcinoma · score 0.23
- cutaneous melanoma · score 0.13
- low grade glioma · score 0.12
- neuroblastoma · score 0.11
- neoplasm · score 0.08
- Idiopathic hypercalciuria · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q99677-F1 | alphafold | PREDICTED | 82.57 | — |
Amino-acid sequence (370 residues)
MGDRRFIDFQ FQDSNSSLRP RLGNATANNT CIVDDSFKYN LNGAVYSVVF ILGLITNSVS LFVFCFRMKM RSETAIFITN LAVSDLLFVC TLPFKIFYNF NRHWPFGDTL CKISGTAFLT NIYGSMLFLT CISVDRFLAI VYPFRSRTIR TRRNSAIVCA GVWILVLSGG ISASLFSTTN VNNATTTCFE GFSKRVWKTY LSKITIFIEV VGFIIPLILN VSCSSVVLRT LRKPATLSQI GTNKKKVLKM ITVHMAVFVV CFVPYNSVLF LYALVRSQAI TNCFLERFAK IMYPITLCLA TLNCCFDPFI YYFTLESFQK SFYINAHIRM ESLFKTETPL TTKPSLPAIQ EEVSDQTTNN GGELMLESTF
Explore Lysophosphatidic acid receptor 4 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets